CN Mobile Logo

Search form


Breast Cancer

70-Gene Signature Could Help Early-Stage Breast Cancer Patients Avoid Chemotherapy

Using a 70-gene signature test could identify many women with early-stage breast cancer considered to be at high clinical risk who do not actually need chemotherapy. Image © anyaivanova / Shutterstock.com.

Breast Cancer

The ASCO-CAP guidelines for HER2 gene amplification testing leave some patients at risk for misclassification and inappropriate treatment.

The FDA has approved ribociclib in combination with an aromatase inhibitor for the first-line treatment of postmenopausal women with advanced, HR-positive/HER2-negative breast cancer.

Surgical oncologists can help reduce the risk of patients developing opioid dependence.

The United States Medicare Access and CHIP Reauthorization Act of 2015 quality- and payment-related provisions took effect January 1, 2017, and how oncologists comply this year will determine their payments in 2019.

Despite breast tumors’ lower mutational loads than lung cancers and melanoma—cancers in which immunotherapy have shown particular promise—breast cancers are nevertheless immunogenic.

Breast conservation therapy is usually best for local treatment for stage II breast cancer—and biology, as well as stage, drives patient outcomes.

Refining the American Joint Committee on Cancer breast cancer staging system to include molecular tumor markers will improve patient risk stratification and determination of prognosis.


Subscribe to Breast Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.